Viracta Therapeutics, Inc. announced that Chief Medical Officer, Lisa Rojkjaer, M.D., will be leaving the company to pursue another opportunity, effective May 5, 2023. Donald Strickland, M.D., Viracta's Vice President, Clinical Development and Medical Director, and Yisrael Katz, M.D., Senior Medical Director, will continue to oversee Viracta's pivotal NAVAL-1 trial and solid tumor clinical program, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.481 USD | -1.84% |
|
-16.78% | -15.61% |
Jun. 12 | XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher | MT |
May. 30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.61% | 18.89M | |
+16.59% | 44.44B | |
+42.83% | 40.03B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.29B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Viracta Therapeutics, Inc. Announces Departure of Lisa Rojkjaer as Chief Medical Officer